Table 1.
Demographic and clinical characteristics of the patients in the cohort.
| BM (%) | Non-BM (%) | p * | |
|---|---|---|---|
| Age (years) | 0.127 | ||
| <50 | 31 (15.90%) | 7,602 (13.14%) | |
| 50–59 | 54 (27.69%) | 13,076 (22.61%) | |
| 60–69 | 51 (26.16%) | 14,704 (25.42%) | |
| 70–79 | 33 (16.92%) | 11,981 (20.72%) | |
| ≥80 | 26 (13.33%) | 10,471 (18.11%) | |
| Race | 0.252 | ||
| White | 156 (80.00%) | 43,692 (75.55%) | |
| Black | 22 (11.28%) | 6,955 (12.02%) | |
| Other† | 17 (8.72%) | 7,187 (12.43%) | |
| Gender | 0.160 | ||
| Male | 91 (46.67%) | 29,902 (51.70%) | |
| Female | 104 (53.33%) | 27,932 (48.30%) | |
| Location | 0.057 | ||
| Right side | 83 (42.56%) | 25,340 (43.82%) | |
| Left side | 46 (23.59%) | 16,942 (29.29%) | |
| Rectum | 66 (33.85%) | 15,552 (26.89%) | |
| Grade | <0.001 | ||
| Grade I | 2 (1.03%) | 4,479 (7.75%) | |
| Grade II | 76 (38.97%) | 37,371 (64.62%) | |
| Grade III | 38 (19.49%) | 8,093 (13.99%) | |
| Grade IV | 6 (3.08%) | 1,534 (2.65%) | |
| Unknown | 73 (37.43%) | 6,357 (10.99%) | |
| Histology | <0.001 | ||
| AC | 172 (88.21%) | 51,579 (89.18%) | |
| MC | 4 (2.05%) | 3,833 (6.63%) | |
| SRCC | 4 (2.05%) | 615 (1.07%) | |
| Other | 15 (7.69%) | 1,807 (3.12%) | |
| pT | <0.001 | ||
| T1–2 | 34 (17.44%) | 17,519 (30.29%) | |
| T3–4 | 76 (38.97%) | 36,520 (63.15%) | |
| Unknown | 85 (43.59%) | 3,795 (6.56%) | |
| pN | <0.001 | ||
| N0–N1b | 95 (48.72%) | 46,957 (81.19%) | |
| N2a–2b | 28 (14.36%) | 8,014 (13.86%) | |
| Unknown | 72 (36.92%) | 2,863 (4.95%) | |
| Bone metastases | <0.001 | ||
| No/Unknown | 154 (78.97%) | 57,302 (99.08%) | |
| Yes | 41 (21.03%) | 532 (0.92%) | |
| Liver metastases | <0.001 | ||
| No/Unknown | 76 (38.97%) | 49,905 (86.29%) | |
| Yes | 119 (61.03%) | 7,929 (13.71%) | |
| Lung metastases | <0.001 | ||
| No/Unknown | 94 (48.21%) | 55,196 (95.44%) | |
| Yes | 101 (51.79%) | 2,638 (4.56%) | |
| CEA | <0.001 | ||
| Negative/Unknown | 78 (40.00%) | 41,425 (71.63%) | |
| Positive | 117 (60.00%) | 16,409 (28.37%) | |
| Perineural Invasion | 0.174 | ||
| None/Unknown | 182 (93.33%) | 52,322 (90.47%) | |
| Present | 13 (6.67%) | 5,512 (9.53%) | |
| Surgery | <0.001 | ||
| None/unknown | 139 (71.28%) | 7,648 (13.22%) | |
| Performed | 56 (28.72%) | 50,186 (86.78%) | |
| Radiotherapy | <0.001 | ||
| None/unknown | 66 (33.85%) | 50,133 (86.68%) | |
| Performed | 129 (66.15%) | 7,701 (13.32%) | |
| Systematic therapy | 0.096 | ||
| None | 127 (65.13%) | 36,560 (63.22%) | |
| Before surgery | 7 (3.60%) | 4,449 (7.69%) | |
| After surgery | 61 (31.27%) | 16,825 (29.09%) |
AC, adenocarcinoma; MC, Mucinous adenocarcinoma; SRCC, Signet ring cell carcinoma.
∗p-values were made by chi-square test.
†Other = American Indian/AK Native, and Asian/Pacific Islander.